about
Clinical applications of PD-L1 bioassays for cancer immunotherapy.Syk inhibitors in clinical development for hematological malignancies.Clinical trials of CAR-T cells in ChinaRecent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.SRSF2 mutations in myelodysplasia/myeloproliferative neoplasmsCytokine release syndrome: grading, modeling, and new therapyUniversal CARs, universal T cells, and universal CAR T cellsDecreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspectiveClinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemiaClinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemiaInotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphomaAntibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myelomaGilteritinib: a novel FLT3 inhibitor for acute myeloid leukemiaRecent updates on CAR T clinical trials for multiple myelomaGemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemiaRecent advances on blinatumomab for acute lymphoblastic leukemiaFrontline therapies for untreated chronic lymphoid leukemia
P50
Q33702815-D9F83DAF-FC59-47AB-BEAE-070B9F80404FQ42011012-D371C171-591F-425F-889B-420D219AF72BQ42654456-58FB257D-C3E2-40FC-A71B-4AB5222E34E7Q47157402-2607BBC7-8465-427C-A96B-9C405EF06199Q55193924-A83E8D7E-A8C1-47E9-99B5-1032897A1567Q57069030-E66E2D73-CE45-49D9-BE8A-2840451C6606Q58700983-52852838-E73D-4A5E-85AD-B14FC070ABB0Q59326961-390D77B1-0728-4021-B813-9DDE3A69B9B9Q60045002-3A1F857B-D3D1-476A-9D2B-8231D671C187Q61797408-4091B421-A41B-4AA8-BF68-FD96E1205460Q64005145-16597E6B-E014-4760-8AE4-E9BBD18BC549Q64053139-53885267-4501-4D99-AE9D-27A808ADB121Q89998321-651E5114-73C9-4750-99A9-D2B1655AE2E9Q90137004-3772414E-08E8-414F-A497-F9D5D717FF8FQ91101866-97CC9EA6-29EA-4BCC-A936-9FE223B8CA83Q91155595-1498BE29-7337-427B-8DC0-3B8518B45F3DQ91219185-77C8D92D-9808-4FBF-BEB7-177EE021A91CQ92715263-14BCF5F3-2E4D-45C1-8BC9-F4D841CF7EDB
P50
description
researcher
@en
name
Delong Liu
@en
type
label
Delong Liu
@en
prefLabel
Delong Liu
@en
P31
P496
0000-0003-4502-4949